Galderma Group AGXSWX:GALD +4.24%15 PE Ratio (TTM) is 89.76 as of Jun. 30, 2026, which is 26% below its 10-year median of 121.33. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 635 Drug Manufacturers companies, Galderma Group AG ranks worse than 89.92% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-30), Galderma Group AG's share price is
CHF185.80.
Galderma Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF2.07. Therefore, Galderma Group AG's PE Ratio (TTM) for today is 89.76.
The historical rank and industry rank for Galderma Group AG's PE Ratio (TTM) or its related term are showing as below:
XSWX:GALD'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 69.11 Med: 121.33 Max: 189.71
Current: 89.76
During the past 5 years, the highest PE Ratio (TTM) of Galderma Group AG was 189.71. The lowest was 69.11. And the median was 121.33.
XSWX:GALD's PE Ratio (TTM) is ranked worse than 89.92% of 635
companies
in the Drug Manufacturers industry
Industry Median: 20.28
vs XSWX:GALD: 89.76
Galderma Group AG's EPS (Basic) for the
six
months ended in Dec. 2025 was CHF1.42.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF2.09.
Galderma Group AG (XSWX:GALD) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Galderma Group AG PE Ratio (TTM) Related Terms
Galderma Group AG PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: PE Ratio (TTM) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Galderma Group AG's Share Price of today is CHF185.80.
For company reported semi-annually, Galderma Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF2.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Galderma Group AG (XSWX:GALD) has a PE Ratio (TTM) of 89.76 as of Jun. 30, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Galderma Group AG and its competitors. This is 26% below median its historical median of 121.33. Over the past decade, Galderma Group AG's PE Ratio (TTM) has ranged from 69.11 to 189.71. According to the industry distribution chart, Galderma Group AG ranks #571 out of 635 companies in the Drug Manufacturers industry, placing it in the top 89.9%.
Is Galderma Group AG's PE Ratio (TTM) too high?
Galderma Group AG's current PE Ratio (TTM) of 89.76 is 26% below median its 10-year median of 121.33. Over the past 10 years, this metric has ranged from a low of 69.11 to a high of 189.71. The Drug Manufacturers industry median PE Ratio (TTM) is 20.28. Galderma Group AG's value of 89.76 is 342.6% above this industry median. Based on the distribution chart, Galderma Group AG ranks #571 out of 635 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's PE Ratio (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #571 out of 635 companies for PE Ratio (TTM). This places Galderma Group AG in the lower half of its industry. The industry median PE Ratio (TTM) is 20.28. Galderma Group AG's value of 89.76 is 342.6% above this benchmark. Historically, Galderma Group AG's own PE Ratio (TTM) has ranged from 69.11 to 189.71 over the past decade. While the company's 10-year median is 121.33 vs. the industry median of 20.28, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 20.28, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current PE Ratio (TTM) of 89.76 is 342.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 20.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current PE Ratio (TTM) is 89.76, which is 26% below median its own 10-year median of 121.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current PE Ratio (TTM) of 89.76. The current PE Ratio (TTM) is 89.76, which is 26% below median its 10-year median of 121.33 and 342.6% above the Drug Manufacturers industry median of 20.28. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current PE Ratio (TTM) is 89.76 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 